Could diabetes drugs help kidney patients avoid anemia?

NCT ID NCT07063316

First seen Mar 06, 2026

Summary

This study looks at whether SGLT2 inhibitors, a type of diabetes drug, can help prevent or manage anemia in people with chronic kidney disease. Researchers will analyze data from 15,000 patients in Japan to see how these drugs affect anemia rates, treatments, and costs. The goal is to better understand the link between SGLT2 inhibitors and anemia in this population.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Nippon Boehringer Ingelheim Co ., Ltd.

    Tokyo, 1416017, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SGLT2 inhibitor

What this could lead to

If successful, this could help doctors understand whether SGLT2 inhibitors help prevent or manage anemia in kidney disease patients.

What could go wrong

This is an observational study, not a treatment trial, so it cannot prove cause and effect. Results may not apply outside Japan.

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.